Teladoc Health stock
TDOCNYSETeladoc Health, Inc., HealthcareISIN US87918A1051
47Score 47 out of 100, Weak
Price and trend
83 / 100
Price history
+16% in one yearThe chart shows daily closes over 11 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 32% above it.
Since November 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 72).
The price is 11% below its 52-week high. Largest decline in 11 years: 98% (February 2021 to February 2026).
Chart figures for advanced users
- SMA 50$6.71
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$6.60
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)72
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$4.47
- The lowest closing price of the last twelve months.
- Resistance$9.72
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Teladoc Health, Inc. belongs to the Medical (Healthcare Information Services) industry (United States) and, with a market value of $1.58B, is number 13 of 25 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $2.53B (down 1.5% year on year) and a loss of $200.32M.
- For fiscal 2026, analysts expect on average revenue of $2.42B (down 4.4%) and adjusted earnings per share of −$0.84.
Show more
- MEQIRI Score 47 out of 100 (Weak): rank 438 of 714 in Healthcare, median 53.
- Our model puts fair value at $6.47, with the price 38% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
None of our strength checks applies.
Weaknesses
- DilutionShare count up 95% since 2020.Capital allocation 18
- Loss-makingLoss of $154.82M over the last 12 months.Fundamentals 23
- Volatile share priceVolatility 66% a year over the last 12 months.Stability 34
Its standout strengths are momentum and technical analysis, while fundamentals and capital allocation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
- high price swings
What lowers it
- price near its 52-week high
Valuation
Valuation signal
Modestly overvaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $4.32 and expensive above $12.95 (uncertainty very high, based on the price swings of the past year).
Calculated with a cost of equity of 10.7%. At 11.7% the fair value would be $6.26, at 9.7% it would be $6.72.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue fell 2.4% on the twelve months before. Revenue has grown strongly since 2013, at around 50% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 70%, operating −10%, net −8%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 24 Feb 2027in 104 days
- Last reported
- 28 Oct 2026EPS reported −$0.15 (expected −$0.22)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$0.84+2.4%
- Revenue
- $2.42B+0.5%
- Earnings per share
- −$0.62+2.5%
- Revenue
- $2.35B−1.1%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +35.3%Teladoc raised its full year 2026 outlook slightly: revenue now expected at 2.39 to 2.44 billion and adjusted EBITDA at 277 to 303 million, both a bit higher than before, driven by stronger BetterHelp insurance and integrated care performance.
“On a consolidated basis, we now expect 2026 revenue of $2.39 billion to $2.44 billion This represents a $13 million increase at the midpoint versus the prior range. Driven largely by the updated BetterHelp outlook.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 28 Oct 2026 (fiscal Q3 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 6 insiders sold, $1M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Nueno CarlosSale
6 Nov 2026, President, International
- Shares
- 29,432
- Price
- $9.20
- Value
- $270,774
- Catapano Joseph RonaldSale
2 Oct 2026, Chief Accounting Officer
- Shares
- 655
- Price
- $5.65
- Value
- $3,703
- Divita Charles IiiSale
11 Sept 2026, CHIEF EXECUTIVE OFFICER
- Shares
- 17,805
- Price
- $6.10
- Value
- $108,682
Show 13 more
- Rodrigues Fernando M.Sale
3 Sept 2026, President of BetterHelp
- Shares
- 9,812
- Price
- $6.51
- Value
- $63,876
- Nueno CarlosSale
2 Sept 2026, President, International
- Shares
- 6,200
- Price
- $6.30
- Value
- $39,066
- Vandervoort Adam CSale
2 Sept 2026, CHIEF LEGAL OFFICER, SECRETARY
- Shares
- 7,573
- Price
- $6.30
- Value
- $47,717
- Bliss KellySale
2 Sept 2026, President, U.S. Group Health
- Shares
- 7,357
- Price
- $6.30
- Value
- $46,356
- Catapano Joseph RonaldSale
2 Sept 2026, Chief Accounting Officer
- Shares
- 274
- Price
- $6.30
- Value
- $1,726
- Divita Charles IiiSale
2 Sept 2026, CHIEF EXECUTIVE OFFICER
- Shares
- 18,327
- Price
- $6.30
- Value
- $115,478
- Rodrigues Fernando M.Sale
2 Sept 2026, President of BetterHelp
- Shares
- 5,439
- Price
- $6.30
- Value
- $34,271
- Bliss KellySale
6 Jul 2026, President, U.S. Group Health
- Shares
- 2,500
- Price
- $9.50
- Value
- $23,750
- Catapano Joseph RonaldSale
2 Jul 2026, Chief Accounting Officer
- Shares
- 653
- Price
- $9.10
- Value
- $5,942
- Bliss KellySale
1 Jul 2026, President, U.S. Group Health
- Shares
- 2,500
- Price
- $9.00
- Value
- $22,500
- Bliss KellySale
29 Jun 2026, President, U.S. Group Health
- Shares
- 2,500
- Price
- $8.50
- Value
- $21,250
- Divita Charles IiiSale
11 Jun 2026, CHIEF EXECUTIVE OFFICER
- Shares
- 18,074
- Price
- $6.94
- Value
- $125,470
- Rodrigues Fernando M.Sale
3 Jun 2026, President of BetterHelp
- Shares
- 9,572
- Price
- $7.40
- Value
- $70,833
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Teladoc Health
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 47
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Healthcare Information Services)
The next larger and next smaller companies by market value
- HeartflowHTFL $5.14B46
- Privia Health GroupPRVA $3.07B58
- CertaraCERT $1.79B54
- OmnicellOMCL $1.64B50
- GoodRx HoldingsGDRX $1.25B58
- Omada HealthOMDA $945.45M44
- HealthStreamHSTM $883.61M62
- PhreesiaPHR $795.13M55
ETFs that hold Teladoc Health
Held by 13 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Global X Telemedicine & Digital Health UCITS ETFDDOC | 1.90% | 0.68% | €5.31M |
| Avantis Global Small Cap Value UCITS ETFAVWS | 0.15% | 0.39% | €1.47B |
| iShares Ageing Population UCITS ETF2B77 | 0.14% | 0.40% | €807M |
Show 5 more
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.07% | 0.30% | €185.82M |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.05% | 0.30% | €2.17B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.05% | 0.30% | €4.22B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.05% | 0.30% | €944.34M |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.02% | 0.45% | €1.53B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Jul 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.